Singulex Receives US Patent for Cardiovascular Biomarker Assay, Begins Planning FDA Submission

The patent follows on one the company received last year for the Erenna platform itself, and comes as it begins efforts to develop the assay as a clinical diagnostic that it hopes to submit for US Food and Drug Administration approval within the next two years.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.